Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;101(5):223-232.
doi: 10.1212/WNL.0000000000207166.

Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology

Kathryn A Kvam  1 , Michael Benatar  1 , Alisa Brownlee  1 , Tracie Caller  1 , Rohit R Das  1 , Phil Green  1 , Sherry Kolodziejczak  1 , John Russo  1 , Danica Sanders  1 , Nadia Sethi  1 , Kara Stavros  1 , Julie Stierwalt  1 , Nancy Giles Walters  1 , Amy Bennett  1 , Scott R Wessels  1 , Benjamin Rix Brooks  1
Affiliations

Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology

Kathryn A Kvam et al. Neurology. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

K.A. Kvam has received personal compensation for serving as Deputy Editor of Neurology Clinical Practice. M. Benatar has received personal compensation in the range of $10,000-$49,999 for serving as a consultant for Biogen, personal compensation in the range of $500-$4,999 for serving as a consultant for Jazz Pharmaceuticals, personal compensation in the range of $10,000-$49,999 for serving as a consultant for Alexion, personal compensation in the range of $500-$4,999 for serving as a consultant for Annexon, personal compensation in the range of $500-$4,999 for serving as a consultant for UCB, personal compensation in the range of $500-$4,999 for serving as a consultant for UniQure, personal compensation in the range of $5,000-$9,999 for serving as a consultant for Immunovant, personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis, and intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a consultant for Arrowhead. A. Brownlee has received personal compensation for serving as an employee of RESNA. T. Caller has no disclosures to report. R.D. Das has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Janicek. The institution of an immediate family member of Dr. Das has received research support from the NIH. P. Green, S. Kolodziejczak, J. Russo, and D. Sanders have no disclosures to report. N. Sethi has received personal compensation for serving as an employee of ALS TDI, personal compensation in the range of $500-$4,999 for serving as a consultant for Cytokinetics, personal compensation in the range of $500-$4,999 for serving as a consultant for IONIS Pharmaceuticals, personal compensation in the range of $500-$4,999 for serving as a consultant for Biogen, and personal compensation in the range of $500-$4,999 for serving as a consultant for Merck. K. Stavros has no disclosures to report. J. Stierwalt has received research support from the NIH and publishing royalties from a publication relating to health care. The institution of Julie Stierwalt has received research support from the NIH. N. Giles Walters has no disclosures to report. A. Bennett and S.R. Wessels are employees of the American Academy of Neurology. B. R. Brooks has received personal compensation in the range of $500-$4,999 for serving as a consultant for ITF Pharma, personal compensation in the range of $500-$4,999 for serving as a consultant for Mitsubishi Tanabe Pharma America, personal compensation in the range of $5,000-$9,999 for serving as a consultant for MediciNova, personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science, personal compensation in the range of $500-$4,999 for serving on a speakers bureau for Mitsubishi Tanabe Pharma America, personal compensation in the range of $5,000-$9,999 for serving on a speakers bureau for Cytokinetics, research support from Alexion, and personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry and has a noncompensated relationship as a Member ALS Quality Measures Subcommittee with American Academy of Neurology that is relevant to AAN interests or activities. The institution of Dr. Brooks has received research support from Orion, Mitsubishi Tanabe Pharma America, and Biohaven. Go to Neurology.org/N for full disclosures.

Figures

Figure
Figure. Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update Process Flow
See this image and copyright information in PMC

References

    1. Mehta P, Raymond J, Punjani R, et al. . Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(3-4):220-225. doi:10.1080/21678421.2021.1949021 - DOI - PubMed
    1. Nelson LM, Topol B, Kaye W, et al. . Evaluation of the completeness of ALS case ascertainment in the US national ALS Registry: application of the capture-recapture method. Neuroepidemiology. 2022;56(2):104-114. doi:10.1159/000521591 - DOI - PubMed
    1. Xu L, Liu T, Liu L, et al. . Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944-953. doi:10.1007/s00415-019-09652-y - DOI - PubMed
    1. Westeneng HJ, Debray TPA, Visser AE, et al. . Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433. doi:10.1016/s1474-4422(18)30089-9 - DOI - PubMed
    1. Luo L, Song Z, Li X, et al. . Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci. 2019;40(2):235-241. doi:10.1007/s10072-018-3653-2 - DOI - PubMed

Publication types